Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Heidelberg Pharma AG (0QW5) Share Price & Analysis

0QW5 Stock Chart & Stats

€2.02-€0.18(-8.18%)
At close: 10:16 AM GMT
€2.2€2.4€2.63 Aug17 Aug31 Aug14 Sep28 Sep12 Oct29 Oct
Day’s Range
EUR 2.20 - EUR 2.20
52-Week Range
EUR 2.10 - EUR 3.31
Previous Close
EUR 2.10
Volume
N/A
Average Volume (3M)
60
Market Cap
EUR 98.71M
Enterprise Value
EUR 152.89M
Total Cash (Recent Filing)
EUR 19.84M
Total Debt (Recent Filing)
EUR 298.96K
Price to Earnings (P/E)
―
Beta
0.48
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Recent revenue growth indicates that the company is generating greater commercial or partnered-program activity than in the prior period. If this expansion continues, it could provide a broader base over which to spread research and operating costs and support eventual progress toward profitability.

High Gross Margin

The high gross margin shows that recognized revenue has attractive economics before operating expenses are considered. This creates potential operating leverage if revenue scales, because additional revenue could contribute meaningfully toward covering research, development, and corporate costs over time.

Targeted Oncology Platform

The ATAC platform gives Heidelberg Pharma a defined oncology development model centered on targeted delivery of a potent payload. Internal and partnered programs can diversify development opportunities and provide multiple routes for the technology to generate future value.

Bears Say

Deep And Recurring Losses

Severe and recurring losses show that current revenue is not yet sufficient to support the company’s research and operating structure. Unless revenue scales materially or costs are reduced, continued losses can weaken financial flexibility and delay the point at which the business becomes self-funding.

Sustained Cash Burn

Persistent negative operating and free cash flow means the business is consuming cash rather than replenishing it through operations. This raises the need for additional financing or strategic funding and leaves less flexibility to sustain development programs if funding conditions become less favorable.

Negative Equity

The move to negative equity represents a significant deterioration in capital structure and leaves little balance-sheet cushion against further losses. It increases dependence on future capital raises or strategic funding, potentially limiting management’s flexibility in financing long-term development.

0QW5 FAQ

What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest share price was €2.10 and its highest was €3.31 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €98.71M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Heidelberg Pharma AG’s earnings last quarter?
Heidelberg Pharma AG released its earnings results on Jul 15, 2026. The company reported €0.018 earnings per share for the quarter.
Is Heidelberg Pharma AG overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,784,317 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Heidelberg Pharma AG reported an EPS of €0.018 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in GB:0QW5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology